GlassScriptPhysician profile
Nicole Scott
NPI 1164858882
$30,474.94
in general payments reported to CMS, 2019-2025
48 companies · $31.32 in 2025
The $31.32 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,148 · 2022: $14K · 2023: $11K · 2024: $135 · 2025: $31.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,850 · Travel and Lodging: $2,825 · Food and Beverage: $2,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,850.00 |
| Travel and Lodging | $2,825.16 |
| Food and Beverage | $2,103.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $24,295.31 | 2021-2023 | Verzenio, Jaypirca |
| Seagen INC. | $614.33 | 2021-2023 | Adcetris, Padcev, Tukysa |
| E.R. Squibb & Sons, L.L.C. | $533.04 | 2021-2024 | Opdivo, Opdualag |
| Celgene Corporation | $485.62 | 2022-2023 | Pomalyst, Reblozyl, Opdualag |
| Janssen Biotech, INC. | $441.35 | 2021-2024 | Darzalex, Tecvayli, Imbruvica |
| Incyte Corporation | $415.56 | 2021-2023 | Jakafi |
| Amgen INC. | $401.39 | 2021-2023 | Nplate, Vectibix, Xgeva |
| Pharmacyclics LLC, An Abbvie Company | $378.26 | 2021-2023 | Imbruvica |
| Novartis Pharmaceuticals Corporation | $358.80 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $281.76 | 2022-2023 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $248.45 | 2021-2023 | Calquence |
| Eisai INC. | $247.84 | 2021-2023 | |
| Pfizer INC. | $236.63 | 2021-2023 | |
| Astellas Pharma US INC | $137.60 | 2021-2024 | Padcev |
| Daiichi Sankyo INC. | $127.85 | 2021-2024 | Enhertu |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.